Trump's tariffs will not only impact sponsors, but higher costs will ripple down the clinical trial supply chain in the US.

Rocket Pharmaceuticals, Inc.'s innovative therapies show promise after FDA setbacks. With potential $1B+ markets, RCKT offers ...

WASHINGTON, February 12. /TASS/. Russia and the United States intend to immediately start negotiations on the settlement of the Ukrainian conflict, US President Donald Trump said after a telephone ...

Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...

Scotiabank analyst Greg Harrison raised the firm’s price target on BridgeBio (BBIO) to $49 from $48 and keeps an Outperform rating on the ...

Shares of BridgeBio Pharma (NASDAQ:BBIO), currently valued at $5.88 billion, witnessed an uptick as Scotiabank (TSX:BNS) analyst Greg Harrison increased the price target to $49 from $48 while ...

Bishop asked about upcoming events. Missling outlined the anticipated schizophrenia trial readout for ANAVEX 3-71 in the first half of 2025, the detailed ATTENTION-AD data presentation in April, and ...

Prices for brand-name drugs in the U.S. are three times what the same drugs cost in other countries. And in a recent KFF survey, 3 in 10 adults reported not taking their medicine as prescribed at some ...

As President Trump threatens a wider trade war on EU and other allies, an obscure global tax battle could be one retaliatory ...

The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...

Despite President Donald Trump’s stated concern over fentanyl trafficking and national security threats, his Department of ...

Rare diseases have become an attractive target for pharmaceutical companies both on the ASX and internationally.